A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gilles Salles, PhD
CHU Lyon - Sud - LYSA
Study Chair - Loïc YSEBAERT, MD
CHU de Toulouse LYSA
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hopital Henri Mondor
Créteil, France
- Chu de Lille
Lille, France
- Institut Paoli Calmette
Marseille, France
- Chu de Nantes
Nantes, France
- Chu Lyon Sud
Pierre-Bénite, France
- Chu de Toulouse
Toulouse, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2013
- Primary completion
- 30 Nov 2014
- Completion
- 31 Jan 2018
- Last update posted
- 7 Mar 2018
- Registered enrollment
- 18
- Registry id
- NCT01766583
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.